Send me real-time posts from this site at my email

March 25 - Trading List: Updates, Analyst Actions, Our Take - CRIS

Notable updates, news, or analysts actions from our trading lists followed by 'Our Take'.

Curis initiated with a Buy at B. Riley Securities

B. Riley Securities analyst Justin Walsh initiated coverage of Curis with a Buy rating and $19 price target, which represents a potential 57% increase from current levels. The full potential of the company's lead clinical asset, CA-4948, "remains underappreciated" in what could be an $12B net market opportunity across multiple blood cancer indications, Walsh tells investors in a research note. The analyst estimates that CA-4948 could generate risk-adjusted peak revenues of $181M in initial lymphoma indications, $680M as a combination in ibrutinib-treated lymphoma indications, and $339M in leukemia and related blood cancers.

Our Take:  "On our watch list / new idea. A high risk/high reward small biotech in the blood cancer field. We would pay with the options here, rather than the stock."

$CRIS, Curis, Inc. / H1

Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.

If you liked this article, please click the LIKE (thumbs up) button.

Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so)!

Follow us/bookmark us and check back occasionally for additional articles or comments on our page...

Wild Tiger Trading - start/main page.


Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue